MA42616A - Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire - Google Patents

Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire

Info

Publication number: MA42616A
Authority: MA; Morocco
Prior art keywords: etc1002; ezetimibe; risk; treating; reducing
Prior art date: 2015-03-13

Application number

MA042616A

Other languages

English (en)

Inventor

Diane Elaine Macdougall

Roger Schofield Newton

Noah Laban Rosenberg

Original Assignee

Esperion Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-13

Filing date

2016-03-14

Publication date

2021-05-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56920255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-14 Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc

2021-05-19 Publication of MA42616A publication Critical patent/MA42616A/fr

Links

208000024172 Cardiovascular disease Diseases 0.000 title 1
HYHMLYSLQUKXKP-UHFFFAOYSA-N bempedoic acid Chemical compound OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O HYHMLYSLQUKXKP-UHFFFAOYSA-N 0.000 title 1
229940000425 combination drug Drugs 0.000 title 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title 1
229960000815 ezetimibe Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA042616A 2015-03-13 2016-03-14 Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire MA42616A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562133128P	2015-03-13	2015-03-13
US201562250921P	2015-11-04	2015-11-04

Publications (1)

Publication Number	Publication Date
MA42616A true MA42616A (fr)	2021-05-19

Family

ID=56920255

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042616A MA42616A (fr)	2015-03-13	2016-03-14	Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire

Country Status (18)

Country	Link
US (3)	US10912751B2 (fr)
EP (1)	EP3267989A4 (fr)
JP (2)	JP6940411B2 (fr)
KR (1)	KR102370582B1 (fr)
CN (2)	CN114099496A (fr)
AU (3)	AU2016233485B2 (fr)
BR (1)	BR112017019358A2 (fr)
CA (1)	CA2978204A1 (fr)
CL (1)	CL2017002299A1 (fr)
IL (1)	IL254194A0 (fr)
MA (1)	MA42616A (fr)
MX (2)	MX392182B (fr)
PH (1)	PH12017501625A1 (fr)
RU (2)	RU2022102472A (fr)
SG (2)	SG10201908500UA (fr)
UA (1)	UA123355C2 (fr)
WO (1)	WO2016149191A1 (fr)
ZA (1)	ZA201706919B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3267989A4 (fr)	2015-03-13	2018-11-07	Esperion Therapeutics, Inc.	Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2018148417A1 (fr) *	2017-02-08	2018-08-16	Esperion Therapeutics, Inc.	Formulations d'associations de trois principes actifs et méthodes de traitement ou de réduction du risque de maladie cardiovasculaire
US20180338922A1 (en) *	2017-05-26	2018-11-29	Esperion Therapeutics, Inc.	Fixed dose formulations
WO2019179494A1 (fr) *	2018-03-23	2019-09-26	深圳市塔吉瑞生物医药有限公司	Composé d'acide pentadécanedioïque substitué, composition pharmaceutique et utilisation associée
US20210322375A1 (en) *	2018-08-27	2021-10-21	Esperion Therapeutics, Inc.	Combination drug formulations for treating patients with cardiovascular disease and associated conditions
MX2021015936A (es)	2019-06-21	2022-04-26	Esperion Therapeutics Inc	Metodos para preparar acido bempedoico y composiciones del mismo.
CN113134086B (zh) *	2020-01-20	2024-05-24	深圳市长卿医学研究院	一种降血脂的药物组合物
US20240226049A1 (en) *	2023-01-09	2024-07-11	Esperion Therapeutics, Inc.	Methods of treatment using bempedoic acid

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1304093A (en)		1919-05-20		Camera
US3152148A (en)	1963-01-03	1964-10-06	Dow Chemical Co	Preparation of comenic and pyromeconic acids
US3441605A (en)	1965-02-17	1969-04-29	Wallace & Tiernan Inc	Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
GB1196597A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of an Oxido-Cyclodecene
GB1196594A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Improvements in and relating to the production of Sebacic Acid
GB1196595A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a Lactone
FR1545224A (fr)	1966-12-21	1968-11-08	Geigy Ag J R	Procédé de préparation de l'acide sébacique
GB1196598A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a Ketosebacic Acid
GB1196596A (en)	1966-12-21	1970-07-01	Geigy Uk Ltd	Preparation of a hydroxysebacic acid
US3930024A (en)	1969-09-02	1975-12-30	Parke Davis & Co	Pharmaceutical compositions and methods
US3773946A (en)	1969-09-02	1973-11-20	Parke Davis & Co	Triglyceride-lowering compositions and methods
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4281200A (en)	1979-08-30	1981-07-28	The Dow Chemical Company	Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en)	1979-09-04	1981-04-14	Kao Corp	Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en)	1981-12-15	1982-03-31	Yissum Res Dev Co	Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (it)	1983-05-30	1987-04-08	Luso Farmaco Inst	3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
JPS59232811A (ja)	1983-06-16	1984-12-27	Sumitomo Chem Co Ltd	芳香族ポリアミドイミド樹脂成形体の製造方法
JPS60136512A (ja)	1983-12-26	1985-07-20	Eisai Co Ltd	脂質代謝改善剤
DE3423166A1 (de)	1984-06-22	1986-01-02	Epis S.A., Zug	Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4896344A (en)	1984-10-15	1990-01-23	Grady John K	X-ray video system
US4634119A (en)	1985-07-11	1987-01-06	Pesthy Paul K	Resilient exercise machine with body support platform
US4714762A (en)	1986-10-31	1987-12-22	Warner-Lambert Company	Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5166174A (en)	1987-01-28	1992-11-24	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti-ulcers containing same
US5225439A (en)	1987-01-28	1993-07-06	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti ulcers containing same
US5428062A (en)	1987-01-28	1995-06-27	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti ulcers containing same
US4758880A (en)	1987-03-27	1988-07-19	The Grass Valley Group, Inc.	Video matte generator
JP2999579B2 (ja)	1990-07-18	2000-01-17	武田薬品工業株式会社	Ｄｎａおよびその用途
US5254589A (en)	1991-10-15	1993-10-19	Warner-Lambert Company	Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en)	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5420339A (en)	1993-11-22	1995-05-30	Warner-Lambert Company	Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (ja)	1994-04-08	1999-08-23	時久増田	角筒包装袋の製造方法及び装置
US5504073A (en)	1994-07-01	1996-04-02	Warner-Lambert Company	PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5578639A (en)	1994-07-01	1996-11-26	Warner-Lambert Company	PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (sv)	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
US5648387A (en)	1995-03-24	1997-07-15	Warner-Lambert Company	Carboxyalkylethers, formulations, and treatment of vascular diseases
AU720853B2 (en)	1995-11-02	2000-06-15	Warner-Lambert Company	Method and pharmaceutical composition for regulating lipid concentration
US5807846A (en)	1996-11-14	1998-09-15	Warner-Lambert Company	Phosphonamide ACAT inhibitors
IL119971A (en)	1997-01-07	2003-02-12	Yissum Res Dev Co	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en)	1997-04-21	2000-07-25	Warner-Lambert Company	N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en)	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6037323A (en)	1997-09-29	2000-03-14	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en)	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PL341397A1 (en)	1997-11-25	2001-04-09	Warner Lambert Co	Inhibition of lipoprotein oxidation
EP1137634B1 (fr)	1998-12-07	2005-06-15	Schering Corporation	Procede relatif a la synthese d'azetidinones
US6207822B1 (en)	1998-12-07	2001-03-27	Schering Corporation	Process for the synthesis of azetidinones
US6410802B1 (en)	1999-04-01	2002-06-25	Esperion Therapeutics, Inc.	Methods for synthesizing ether compounds and intermediates therefor
US20030180352A1 (en)	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004531459A (ja)	2000-10-11	2004-10-14	エスペリオンセラピューティクス，インコーポレイテッド	コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
US7304093B2 (en)	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
CA2425311C (fr)	2000-10-11	2011-06-14	Esperion Therapeutics, Inc.	Composes de fonction cetone et compositions pour la regulation du taux de cholesterol, et utilisations associees
CN101426763A (zh)	2000-10-11	2009-05-06	埃斯佩里安医疗公司	用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
CN1894195A (zh)	2000-10-11	2007-01-10	埃斯佩里安医疗公司	用于控制胆固醇以及相关用途的醚化合物以及组合物
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7053046B2 (en)	2001-12-21	2006-05-30	Mcgrath Kevin	Peptide activators of VEGF
ES2625429T3 (es)	2003-01-23	2017-07-19	Esperion Therapeutics Inc.	Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
US20050171080A1 (en)	2003-12-23	2005-08-04	Dr. Reddy's Laboratories, Inc.	Polymorphs of ezetimibe and process for preparation thereof
JP2007525408A (ja)	2003-12-24	2007-09-06	エスペリオンセラピューティクス，インコーポレイテッド	コレステロール管理および関連使用のためのケトン化合物および組成物
JP4553181B2 (ja)	2004-03-25	2010-09-29	株式会社サタケ	残留農薬分析方法
US7194579B2 (en)	2004-04-26	2007-03-20	Sun Microsystems, Inc.	Sparse multi-component files
TW200803868A (en)	2005-11-15	2008-01-16	Takeda Pharmaceutical	Novel method for treating hyperlipidemia
CA2682082A1 (fr) *	2007-03-24	2008-10-02	Genzyme Corporation	Administration d'oligonucleotides
US8209479B2 (en)	2007-07-18	2012-06-26	Google Inc.	Memory circuit system and method
PL2965752T3 (pl)	2007-12-10	2025-12-08	Assia Chemical Industries Ltd.	Formulacja farmaceutyczna zawierająca ezetymib
EP2168573A1 (fr)	2008-09-30	2010-03-31	LEK Pharmaceuticals D.D.	Formulations contentant d'ézétimibe
EP2216016A1 (fr)	2009-02-06	2010-08-11	LEK Pharmaceuticals d.d.	Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
ES2382773T3 (es)	2009-03-13	2012-06-13	Sanovel Ilac Sanayi Ve Ticaret A.S.	Composiciones de ezetimiba
JP2013537240A (ja)	2010-09-20	2013-09-30	カリウスセラピューティクスエスエー	糖尿病および脂質異常症の処置のための方法および組成物
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
AR086675A1 (es)	2011-06-14	2014-01-15	Merck Sharp & Dohme	Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
HUE069234T2 (hu) *	2011-09-16	2025-02-28	Regeneron Pharma	Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
MX367352B (es) *	2012-01-06	2019-08-16	Gemphire Therapeutics Inc	Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
EP2838536B1 (fr)	2012-04-18	2017-08-09	Mallinckrodt LLC	Compositions pharmaceutiques à libération immédiate présentant des propriétés de dissuasion d'abus
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
WO2014099584A1 (fr)	2012-12-17	2014-06-26	Merck Sharp & Dohme Corp.	Nouveaux dérivés de pyridine -2-carboxamide, compositions contenant de tels composés et méthodes de traitement associées
EP3267989A4 (fr)	2015-03-13	2018-11-07	Esperion Therapeutics, Inc.	Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (fr)	2015-08-04	2017-02-09	Dezima Pharma B.V.	Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et d'un inhibiteur de citrate lyase d'atp–activateur d'ampk
WO2018148417A1 (fr)	2017-02-08	2018-08-16	Esperion Therapeutics, Inc.	Formulations d'associations de trois principes actifs et méthodes de traitement ou de réduction du risque de maladie cardiovasculaire
US20180338922A1 (en)	2017-05-26	2018-11-29	Esperion Therapeutics, Inc.	Fixed dose formulations
MX2021002090A (es)	2018-08-24	2021-04-28	Esperion Therapeutics Inc	Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.
US20210322375A1 (en)	2018-08-27	2021-10-21	Esperion Therapeutics, Inc.	Combination drug formulations for treating patients with cardiovascular disease and associated conditions

2016
- 2016-03-14 EP EP16765550.5A patent/EP3267989A4/fr active Pending
- 2016-03-14 KR KR1020177029370A patent/KR102370582B1/ko active Active
- 2016-03-14 CA CA2978204A patent/CA2978204A1/fr active Pending
- 2016-03-14 UA UAA201709830A patent/UA123355C2/uk unknown
- 2016-03-14 US US15/558,084 patent/US10912751B2/en active Active
- 2016-03-14 AU AU2016233485A patent/AU2016233485B2/en active Active
- 2016-03-14 CN CN202111400943.XA patent/CN114099496A/zh active Pending
- 2016-03-14 RU RU2022102472A patent/RU2022102472A/ru unknown
- 2016-03-14 SG SG10201908500U patent/SG10201908500UA/en unknown
- 2016-03-14 BR BR112017019358A patent/BR112017019358A2/pt not_active Application Discontinuation
- 2016-03-14 CN CN201680015467.0A patent/CN107530307A/zh active Pending
- 2016-03-14 WO PCT/US2016/022319 patent/WO2016149191A1/fr not_active Ceased
- 2016-03-14 RU RU2017136180A patent/RU2766085C2/ru active
- 2016-03-14 SG SG11201707497UA patent/SG11201707497UA/en unknown
- 2016-03-14 JP JP2017548215A patent/JP6940411B2/ja active Active
- 2016-03-14 MA MA042616A patent/MA42616A/fr unknown
- 2016-03-14 MX MX2017011499A patent/MX392182B/es unknown
2017
- 2017-08-28 IL IL254194A patent/IL254194A0/en unknown
- 2017-09-07 PH PH12017501625A patent/PH12017501625A1/en unknown
- 2017-09-07 MX MX2022005469A patent/MX2022005469A/es unknown
- 2017-09-12 CL CL2017002299A patent/CL2017002299A1/es unknown
- 2017-10-12 ZA ZA2017/06919A patent/ZA201706919B/en unknown
2020
- 2020-12-29 US US17/136,870 patent/US11744816B2/en active Active
2021
- 2021-08-19 AU AU2021218120A patent/AU2021218120A1/en not_active Abandoned
- 2021-09-02 JP JP2021142938A patent/JP7295179B2/ja active Active
2024
- 2024-03-11 US US18/601,088 patent/US20240398746A1/en active Pending
- 2024-04-02 AU AU2024202106A patent/AU2024202106B2/en active Active

Also Published As

Publication number	Publication date
CN107530307A (zh)	2018-01-02
JP2021193105A (ja)	2021-12-23
US20240398746A1 (en)	2024-12-05
JP7295179B2 (ja)	2023-06-20
US10912751B2 (en)	2021-02-09
RU2017136180A3 (fr)	2019-09-19
NZ736344A (en)	2024-08-30
AU2016233485A1 (en)	2017-11-02
AU2021218120A1 (en)	2021-09-09
RU2766085C2 (ru)	2022-02-07
WO2016149191A1 (fr)	2016-09-22
BR112017019358A2 (pt)	2018-05-08
SG10201908500UA (en)	2019-11-28
JP6940411B2 (ja)	2021-09-29
AU2024202106B2 (en)	2026-01-22
MX2017011499A (es)	2018-03-26
IL254194A0 (en)	2017-10-31
JP2018507901A (ja)	2018-03-22
EP3267989A1 (fr)	2018-01-17
KR20180006887A (ko)	2018-01-19
CL2017002299A1 (es)	2018-03-16
CN114099496A (zh)	2022-03-01
RU2022102472A (ru)	2022-03-15
UA123355C2 (uk)	2021-03-24
MX2022005469A (es)	2022-06-02
EP3267989A4 (fr)	2018-11-07
CA2978204A1 (fr)	2016-09-22
PH12017501625A1 (en)	2018-02-12
US11744816B2 (en)	2023-09-05
RU2017136180A (ru)	2019-04-15
KR102370582B1 (ko)	2022-03-04
AU2024202106A1 (en)	2024-05-02
MX392182B (es)	2025-03-21
ZA201706919B (en)	2022-03-30
SG11201707497UA (en)	2017-10-30
US20180064671A1 (en)	2018-03-08
US20210361605A1 (en)	2021-11-25
AU2016233485B2 (en)	2021-05-20

Publication	Publication Date	Title
MA42616A (fr)	2021-05-19	Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
EP3399972A4 (fr)	2019-09-18	Traitement thérapeutique à faible dose
EP3664796A4 (fr)	2021-05-12	Composition de cannabinoïde enrichie en terpène et procédé de traitement
EP3644996A4 (fr)	2021-03-17	Procédés de traitement de la maladie de huntington
IL290993A (en)	2022-05-01	Methods of diagnosing and treating tourette syndrome
EP3370617A4 (fr)	2019-08-07	Système non invasif d'imagerie et de traitement des arythmies cardiaques
EP3490582A4 (fr)	2020-04-01	Méthodes et compositions de traitement de maladie.
HUE071243T2 (hu)	2025-08-28	Mikro-disztrofin bejuttatása adeno-asszociált vírus vektorral izomdisztrófia kezelésére
EP3341392A4 (fr)	2019-01-23	Compositions et procédés de traitement de la douleur
HUE057795T2 (hu)	2022-06-28	Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására
MA47613A (fr)	2020-01-01	Compositions et procédés de traitement du cancer
EP3374502A4 (fr)	2019-07-10	Procédés pour le traitement de dystrophies cornéennes
EP3377516A4 (fr)	2019-06-26	Procédés et compositions pour le traitement du cancer
MA41115A (fr)	2017-10-10	Procédé de traitement de la maladie d'alzheimer
EP3326559A4 (fr)	2019-04-10	Instrument de traitement aux ultrasons, et ensemble de traitement aux ultrasons
EP3331612A4 (fr)	2019-07-03	Procédés et compositions destinés à la thérapie de tumeurs
EP3307329A4 (fr)	2019-05-15	Traitement et diagnostic du cancer
EP3355892A4 (fr)	2019-05-22	Procédés de traitement de dystrophie musculaire
EP3318267A4 (fr)	2019-02-27	Agent thérapeutique et procédé de traitement de maladie de hunter
EP3469101A4 (fr)	2020-04-22	Procédés et compositions pour le diagnostic et le traitement du cancer de la prostate
EP3697767A4 (fr)	2021-09-01	Composés et procédés de traitement du cancer
EP3352753A4 (fr)	2019-03-13	Molécules de type sphingolipide synthétiques, médicaments, procédés pour leur synthèse et procédés de traitement
BR112017005713A2 (pt)	2018-01-23	composto da fórmula (i), método de mobilização das células-tronco hematopoiéticas (hsc) e células progenitoras endoteliais (epc) na circulação periférica, método de tratamento de lesão tecidual, câncer, doença inflamatória ou doença autoimune, e composição farmacêutica
MA49688A (fr)	2020-06-03	Procédés de traitement du syndrome myélodysplasique
MA42936A (fr)	2018-08-01	Procédé de traitement de blessures cardiaques